News | Antiplatelet and Anticoagulation Therapies | August 31, 2018

Extended Post-Hospital Oral Anticoagulant Use Reduces Non-Fatal Blood Clots

Results from MARINER trial suggest possible relief for large proportion of medically ill patients

Extended Post-Hospital Oral Anticoagulant Use Reduces Non-Fatal Blood Clots

August 31, 2018 — Use of an oral anticoagulant in medically ill patients for 45 days following hospital discharge reduces the rate of non-fatal symptomatic blood clots with no impact on fatal blood clots, according to late breaking results from the MARINER trial. The results were presented in a Hot Line Session at the European Society of Cardiology (ESC) Congress 2018, Sept. 25-28 in Munich, Germany, and published in The New England Journal of Medicine.

Prof. Alex Spyropoulos, study author, of the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, New York, said, “Anticoagulants help prevent blood clots in medically ill patients while they are under our supervision at the hospital. However, the risk of blood clots extends well beyond this period. Our results suggest we may be able to offer further protection to patients at risk from non-fatal blood clots, with no increase in major bleeding, by prescribing an oral anticoagulant for use after discharge. This study has potential to reduce the public healthcare burden of non-fatal blood clots in a large proportion of medically ill patients.”

Each year, around 20 million acutely ill medical patients are hospitalized in the U.S. and EU with conditions such as heart attack, pneumonia, flu, bronchitis, asthma or broken bones. A significant proportion of these patients are at risk of venous thromboembolism (VTE), which includes deep vein thrombosis (DVT) and pulmonary embolism, while in hospital and up to six weeks afterwards. Around 70 percent of hospital-acquired fatal pulmonary embolism occurs in medically ill patients.

Anticoagulants delivered by intravenous drip or injection are recommended to prevent blood clots (called thromboprophylaxis) in medically ill patients while in hospital, but guidelines do not recommend any use of anticoagulants post-discharge. However, after leaving the hospital the rate of symptomatic VTE more than doubles over the first 21 days and is associated with a five-fold increased risk of fatal pulmonary embolism within 30 days post-discharge.

The MARINER trial investigated whether continuing thromboprophylaxis with an oral anticoagulant after discharge could reduce the risk of symptomatic VTE and VTE-related death in medically ill patients at risk for VTE. The trial enrolled 12,024 patients from 671 centers in 36 countries. Patients were 40 years of age or older, had been hospitalized for an acute medical illness, and had other risk factors for VTE as defined by a VTE risk score. The risk score included immobilization for one day or longer, being in intensive care, age over 60 years, limb paralysis, previous VTE, thrombophilia or a D-dimer level more than two times the upper limit of normal.

Patients were randomly allocated to a 45-day course of either once daily oral rivaroxaban 10 mg (7.5 mg in patients with reduced kidney function) or placebo at the time of hospital discharge. The primary efficacy outcome was symptomatic VTE and VTE-related death. The principal safety outcome was major bleeding.

The final analysis included 12,019 patients, of whom 11,962 (99.5 percent) had taken at least one dose of study drug. The average age was 69.7 years and 48 percent were female. Four in 10 patients had been admitted to hospital for heart failure, 27 percent for respiratory insufficiency, 17 percent for infectious disease, 14 percent for ischemic stroke and 2 percent for inflammatory disease.

During the 45-days post-discharge, 50 (0.83 percent) patients taking rivaroxaban had symptomatic VTE or died from VTE-related causes compared to 66 (1.1 percent) taking placebo (p=0.136). When examining symptomatic VTE only, which included lower extremity DVT and non-fatal pulmonary embolism, there were fewer events with rivaroxaban (0.18 percent) compared to placebo (0.42 percent; hazard ratio [HR] 0.44, 95 percent confidence interval [CI] 0.22–0.89, p=0.023).

The researchers also examined an exploratory secondary composite endpoint of symptomatic VTE and all-cause mortality. They found that 1.3 percent of patients taking rivaroxaban experienced an event compared to 1.78 percent of patients in the placebo group (HR 0.73, 95 percent CI 0.54–0.97, p=0.033).

Major bleeding occurred in 17 (0.28 percent) patients in the rivaroxaban group compared to nine (0.15 percent) taking placebo (p=0.124), with very few critical and fatal bleeds and no significant difference between groups.

For more information: www.nejm.org

Reference

1. Spyropoulos A.C., Ageno W., Albers G.W., et al. Rivaroxaban for Thromboprophylaxis after Hospitalization for Medical Illness. New England Journal of Medicine, Aug. 26, 2018. DOI: 10.1056/NEJMoa1805090

Related Content

Fragmin (dalteparin sodium) injection was cleared by the FDA for use in pediatric patients. It was initially approved by the FDA in 1994 for adults and is a type of heparin.

Fragmin (dalteparin sodium) injection is now cleared by the FDA for use in pediatric patients. It was initially approved by the FDA in 1994 for adults and is a type of heparin.

Technology | Antiplatelet and Anticoagulation Therapies | May 17, 2019
May 17, 2019 — The U.S.
PhaseBio Receives FDA Breakthrough Therapy Designation for Ticagrelor Reversal Agent
Technology | Antiplatelet and Anticoagulation Therapies | April 30, 2019
PhaseBio Pharmaceuticals Inc. announced the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy...
People With Heart Disease at Risk When Pharmacies Close
News | Antiplatelet and Anticoagulation Therapies | April 24, 2019
April 24, 2019 — New research from the University of Illinois at Chicago shows that when pharmacies close, people sto
Study Finds Only Six Percent of Patients Taking Statins as Directed
News | Antiplatelet and Anticoagulation Therapies | April 18, 2019
A recent study found patients with atherosclerotic cardiovascular disease cut their risk of a second major adverse...
HonorHealth Research Institute Launches SynIVUS-DAPT Study
News | Antiplatelet and Anticoagulation Therapies | April 16, 2019
HonorHealth Research Institute announced the first patients have been enrolled in the SynIVUS-DAPT Study. The clinical...
Lack of Physician Guidance, Fear of Side Effects Influence Statin Compliance
News | Antiplatelet and Anticoagulation Therapies | April 15, 2019
Despite national guidelines indicating statins can lower risk of heart attack and stroke, many patients who could...
Stopping DAPT After One Month Improved Outcomes in Stent Patients
News | Antiplatelet and Anticoagulation Therapies | March 25, 2019
Patients who stopped taking aspirin one month after receiving a stent in the heart’s arteries but continued taking the...
Apixaban Effective in Specific Cohort of Non-Valvular Atrial Fibrillation Patients
News | Antiplatelet and Anticoagulation Therapies | March 19, 2019
The Bristol-Myers Squibb-Pfizer Alliance announced results from the Phase 4 AUGUSTUS trial evaluating Eliquis (apixaban...
Researchers Develop Reversible, Drug-Free Antiplatelet Therapy
News | Antiplatelet and Anticoagulation Therapies | February 19, 2019
A new reversible, drug-free antiplatelet therapy could reduce the risk of blood clots and potentially prevent cancer...
FDA Approves Portola Pharmaceuticals' Prior Approval Supplement for Andexxa Generation 2 Manufacturing Process
News | Antiplatelet and Anticoagulation Therapies | January 02, 2019
The U.S. Food and Drug Administration (FDA) has approved Portola Pharmaceuticals’ Prior Approval Supplement (PAS) for...
Overlay Init